The Filing Desk

Palisade Bio

PALI · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

PALI · Last close · November 19, 2026
$0.93
Value Palisade Bio yourself

Palisade Bio reported revenue of $0 million in fiscal 2025. The diluted share count rose 3830.2%.

PALISADE BIO, INC. Latest fiscal year ended December 31, 2025 10-K filed March 20, 2026 · 0001357459-26-000004 Updated
Revenue
$0M
 
Net margin
—
 
Net income
−$17M
 
Free cash flow
—
 
Return on equity
−24.5%
129.0 pts
Market cap
$196M
Nov 19 close
P/E
—
Loss: no P/E

Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Share counts and per-share figures for earlier years are restated for stock splits (1-for-14.9254 and 1-for-50 and 1-for-5), so every year is on today's share basis.

Charts show fiscal years, from the 10-K filings.

What Palisade Bio does

Palisade Bio is a clinical-stage biopharmaceutical company, meaning it tests medicines in people and has none approved for sale. It is developing once-daily pills that block an enzyme called PDE4, which plays a role in inflammation and scarring. The pills are prodrugs: they stay inactive until bacteria in the lower intestine switch them on, so the drug acts mainly in the colon and ends of the small intestine.

Its lead candidate, PALI-2108, is being developed for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. The company is working toward a Phase 2 study in ulcerative colitis and early studies in fibrostenotic Crohn's disease, which involves scarring of the intestine. It is also building a biomarker approach to pick patients more likely to respond.

Palisade says it may seek partners, buy rights to new candidates or sell its own. It holds the patent rights to PALI-2108 under a license agreement with Giiant.

Its biggest risks, as it describes them

  • Its business depends on one lead candidate, PALI-2108, which must succeed in trials and win approval.
  • It relies on a license agreement with Giiant for the patents on PALI-2108.
  • It depends on two qualified suppliers for the active ingredient used in its trials.
  • It needs to keep its senior managers and scientists.
From Palisade Bio's annual report on Form 10-K, filed March 20, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Palisade Bio lost money in fiscal 2025: a net loss of $17 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments10121210133
Debt incl. finance leases00000
Net debt (negative means net cash)−10−12−12−10−133
Net debt to EBITDA—————
Debt to equity0.0x0.0x0.0x0.0x0.0x
Interest coverage−17.4x−1,209.3x−871.3x−1,238.2x−1,805.6x
Current ratio4.6x4.9x5.2x3.2x28.9x
Quick ratio4.6x4.9x5.2x3.2x28.9x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Palisade Bio's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $318,135 of Palisade Bio shares on the open market, and 2 insiders sold $420,525.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Nov 17, 2026Robert Baltera Jr.DirectorBought50,000$1.01$50,285Form 4
Jul 9, 2026Robert Baltera Jr.DirectorBought25,000$1.96$49,000Form 4
Jul 8, 2026Robert Baltera Jr.DirectorBought20,000$1.99$39,800Form 4
Jul 7, 2026John David FinleyCEO, CFO, DirectorSold146,798$2.07$303,872Form 4
Jul 7, 2026Mitchell Lawrence JonesChief Medical OfficerSold51,880$2.05$106,354Form 4
Jul 7, 2026Robert Baltera Jr.DirectorBought30,000$2.03$60,900Form 4
Jul 6, 2026Robert Baltera Jr.DirectorBought20,000$2.05$41,000Form 4
Jul 2, 2026Robert Baltera Jr.DirectorBought10,000$1.98$19,800Form 4
Jul 1, 2026Robert Baltera Jr.DirectorBought20,000$1.98$39,600Form 4
Feb 12, 2026John David FinleyCEO, CFO, DirectorSold3,896$1.75$6,818Form 4
Feb 12, 2026Mitchell Lawrence JonesChief Medical OfficerSold1,989$1.75$3,481Form 4
Jan 16, 2026Donald Allen WilliamsDirectorBought5,000$1.67$8,350Form 4
The latest 12 of 13 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score4 of 81 of 82 of 8
Rule of 40———
Altman Z''31.2938.24—
Accruals ratio−7.8%−18.0%−8.2%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailFailFail
Current ratio rosePassFailPass
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassFailFail
F-score4 of 81 of 82 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put Palisade Bio side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Palisade BioFY25—————2
AbbVieFY258.6%24.6%29.1%15.7%2.7x7Compare
AbCellera BiologicsFY25160.6%−289.0%−231.7%———Compare
Abeona TherapeuticsFY25—−1,536.9%−1,448.5%———Compare
AbsciFY25−38.2%−4,297.0%−3,358.3%−162.8%—3Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue00000—0000
Revenue growth56.0%1,500.4%0.0%−94.1%−12.2%———−100.0%—
Gross profit——————————
Research and development1384422671610
Operating income−21−13−8−9−9−42−16−13−15−18
Net income−21−16−5−8−10−27−14−12−14−17
Diluted EPS (US$)−9,487.50−4,500.00−28,275.00−14,250.00−2,790.00−2,546.10−247.95−27.01−10.19−0.30
Diluted shares (millions)00000000156
Cash flow
Cash from operations−16−13−8−7−5−15−13−11−12−11
Capital expenditure000—00000—
Free cash flow−16−13−8—−5−15−13−11−12—
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000030000
Stock-based compensation3211221114
Balance sheet at fiscal year end
Cash and short-term investments2012—5110121210133
Debt incl. finance leases————100000
Total assets231487312161411134
Total liabilities115221053335
Shareholders' equity1186−8−17712118129
Margins and ratios
Gross margin——————————
Operating margin−127,027.2%−5,118.1%−3,176.7%−56,071.8%−68,764.8%——−5,228.0%——
Net margin−129,721.9%−6,025.4%−1,894.1%−54,252.6%−76,346.1%——−4,920.0%——
Free cash flow margin−96,726.6%−5,164.4%−2,959.3%—−35,310.7%——−4,454.8%——
Rule of 40 (growth + FCF margin)−96,670.6%−3,664.1%−2,959.3%—−35,322.8%—————
Return on capital——————————
Return on equity−258.6%−157.9%−67.6%———−143.7%−103.4%−153.6%−24.5%
Return on assets−112.2%−85.9%−45.7%−117.1%−215.0%−342.8%−100.9%−82.5%−115.8%−23.1%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Palisade Bio's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Palisade Bio.